Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sezary Syndrome 1Osteosarcoma 1Neuroblastoma 1Mycosis Fungoides 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Brain Neoplasms 1

Interventions

Gemcitabine 56pembrolizumab 50Cisplatin 43Magnetic Resonance Spectroscopy 27enfortumab vedotin 22Specimen Handling 22Nivolumab 22Cystectomy 18durvalumab 16Carboplatin 16avelumab 15Mitomycin 14atezolizumab 13Docetaxel 13Cystoscopy 12Fluorouracil 11Radiation 9Transurethral Resection of Bladder 8Radiotherapy 8Ipilimumab 8sacituzumab govitecan 7Standard of Care 7Radiosurgery 7Paclitaxel 7Immunoglobulin G 7Disulfides 7erdafitinib 6cemiplimab 6Surveys and Questionnaires 6Surgical Procedures, Operative 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × magrolimab × 1 year × Clear all
NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Hoffmann-La Roche

Phase 1/2 Completed
272 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡